These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23417315)

  • 61. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
    Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
    Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.
    Kong DS; Lee JI; Park K; Kim JH; Lim DH; Nam DH
    Cancer; 2008 May; 112(9):2046-51. PubMed ID: 18338759
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
    Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
    Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial.
    Fitzek MM; Thornton AF; Harsh G; Rabinov JD; Munzenrider JE; Lev M; Ancukiewicz M; Bussiere M; Hedley-Whyte ET; Hochberg FH; Pardo FS
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):131-7. PubMed ID: 11516862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Newly diagnosed high-grade gliomas.
    Giglio P; Villano JL
    Curr Treat Options Neurol; 2010 Jul; 12(4):309-20. PubMed ID: 20842590
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
    Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
    Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
    Kunschner LJ; Fine H; Hess K; Jaeckle K; Kyritsis AP; Yung WK
    Cancer Invest; 2002; 20(7-8):948-54. PubMed ID: 12449727
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
    Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
    J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
    [TBL] [Abstract][Full Text] [Related]  

  • 73. On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images.
    Sengupta A; Agarwal S; Gupta PK; Ahlawat S; Patir R; Gupta RK; Singh A
    Eur J Radiol; 2018 Sep; 106():199-208. PubMed ID: 30150045
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thalidomide as an anti-angiogenic agent in relapsed gliomas.
    Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M
    J Neurooncol; 2001 Jan; 51(1):41-5. PubMed ID: 11349879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of recurrent high-grade gliomas.
    Wen PY; Brandes AA
    Curr Opin Neurol; 2009 Dec; 22(6):657-64. PubMed ID: 19770658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
    Torcuator R; Zuniga R; Loutfi R; Mikkelsen T
    J Neurooncol; 2009 Jul; 93(3):409-12. PubMed ID: 19139822
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
    Aguilera DG; Mazewski C; Hayes L; Jordan C; Esiashivilli N; Janns A; Macdonald TJ
    J Pediatr Hematol Oncol; 2013 Jan; 35(1):e42-6. PubMed ID: 23249962
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.
    Chang SM; Barker FG; Huhn SL; Nicholas MK; Page M; Rabbitt J; Prados MD
    J Neurooncol; 1998 Apr; 37(2):169-76. PubMed ID: 9524096
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.